Atara Biotherapeutics (ATRA) Operating Income (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Operating Income came in at -$3.4 million in Q1 2026, down 108.68% YoY from $38.8 million in Q1 2025, and down 31.45% on a QoQ basis from -$2.6 million in Q4 2025.
Atara Biotherapeutics (ATRA) Operating Income (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Operating Income data on file, last reported at -$3.4 million in Q1 2026.
- Quarterly Operating Income fell 108.68% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.3 million (up 52.88% YoY) and the FY2025 annual result came in at $35.9 million, up 142.98% from the prior year.
- Operating Income retreated to -$3.4 million in Q1 2026, from -$2.6 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $38.8 million in Q1 2025 to a low of -$88.2 million in Q1 2022.
- A 5-year average of -$35.7 million and a median of -$31.2 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income tumbled 122.25% — and 2025, when it surged 224.18%.
- Tracing ATRA's Operating Income over 5 years: stood at -$75.5 million in 2022, then climbed by 20.62% to -$60.0 million in 2023, then soared by 79.65% to -$12.2 million in 2024, then jumped by 79.0% to -$2.6 million in 2025, then slumped by 31.45% to -$3.4 million in 2026.
- The last three Operating Income figures came in at -$3.4 million (Q1 2026), -$2.6 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 133.12 Mn |
| 10 | Atara Biotherapeutics | 141.99 Mn | 125.43 Mn | 439,000.00 | -4.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.72 Mn |
| Mar 31, 2026 | -3.37 Mn |
| Dec 31, 2025 | -2.56 Mn |
| Sep 30, 2025 | -3.57 Mn |
| Jun 30, 2025 | 3.20 Mn |
| Mar 31, 2025 | 38.80 Mn |
| Dec 31, 2024 | -12.20 Mn |
| Sep 30, 2024 | -21.76 Mn |
| Jun 30, 2024 | -18.23 Mn |
| Mar 31, 2024 | -31.25 Mn |
| Dec 31, 2023 | -59.96 Mn |
| Sep 30, 2023 | -69.61 Mn |
| Jun 30, 2023 | -71.41 Mn |
| Mar 31, 2023 | -75.02 Mn |
| Dec 31, 2022 | -75.54 Mn |
| Sep 30, 2022 | -84.62 Mn |
| Jun 30, 2022 | -32.13 Mn |
| Mar 31, 2022 | -88.22 Mn |
| Dec 31, 2021 | -93.40 Mn |
| Sep 30, 2021 | -84.81 Mn |